Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection

J Clin Virol. 2022 Jan:146:105045. doi: 10.1016/j.jcv.2021.105045. Epub 2021 Nov 25.

Abstract

Introduction: Blood donor studies offer a unique opportunity to screen healthy populations for the presence of antibodies to emerging infections. We describe the use of blood donor specimens to track the 'first-wave' of the COVID-19 pandemic in Ireland.

Methodology: A random selection of donor samples received by the Irish Blood Transfusion Service (IBTS) between February and September 2020 (n = 8,509) were screened by multiple commercial SARs-CoV-2 antibody assays. The antibody detection rate was adjusted to the population to determine the SARS-CoV-2 seroprevalence in Ireland.

Results: SARS-CoV-2 antibody detection rose significantly during the first peak of COVID-19 infection, increasing from 0.3% in March, to 2.9% in April (p < 0.0001, The first SARS-CoV-2 antibody positive donor samples were collected on the 17th February 2020, 2 weeks prior to the first official notification. This is the earliest serological evidence of SARS-CoV-2 circulating in the Irish population. Our results also show a significantly higher antibody prevalence in the Capital city and in donors less than 40 years of age.

Conclusions: The present study demonstrates evidence of SARS-CoV-2 antibody reactivity across all age groups and counties. The critical value of blood donor seroprevalence studies is apparent in this report which identified the earliest serological evidence of SARS-CoV-2 infection in Ireland, as well as documenting the evolution of COVID-19 pandemic in Ireland over time.

Keywords: Blood; Donor; Epidemiology; Ireland; SARS-CoV-2; Seroprevalence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • Blood Donors
  • COVID-19*
  • Humans
  • Pandemics
  • SARS-CoV-2*
  • Seroepidemiologic Studies

Substances

  • Antibodies, Viral